Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study

Background: We compared the efficacy, safety, and immunogenicity of MIL60 with reference bevacizumab as first-line treatment in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in this phase 3, randomized, double-blind study. Methods: Patients with untreated advanc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rui Wan, Xiaorong Dong, Qun Chen, Yan Yu, Shujun Yang, Xiaochun Zhang, Guojun Zhang, Yueyin Pan, Sanyuan Sun, Chengzhi Zhou, Wei Hong, Hui Zhao, Lei Yang, Linian Huang, Rong Wu, Aimin Zang, Rui Ma, Lin Wu, Dongqing Lv, Xiuhua Fu, Jianguo Han, Wenxin Li, Jianchun Duan, Kai Wang, Ou Jiang, Yinglan Chen, Zhongliang Guo, Hongjun Gao, Juyi Wen, Shubin Wang, Enfeng Zhao, Gaofeng Li, Lu Yue, Li Liang, Aiping Zeng, Xiaoshan Wang, Yuxi Zhu, Hongming Pan, Zhaoxia Dai, Weineng Feng, Guofang Zhao, Chuan Lin, Chong Li, Na Li, Yangyi Bao, Yinyin Li, Yanjun Su, Min Zhao, Haohui Fang, Yulong Zhu, Yu Zhang, Lieming Ding, Yang Wang, Xiaobin Yuan, Jie Wang
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
MIL60
biosimilar
bevacizumab
equivalence
non-squamous NSCLC
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/fdbc7c412b564497a8805b161236dd76
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares